Latest Insider Transactions at Incyte Corp (INCY)
This section provides a real-time view of insider transactions for Incyte Corp (INCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INCYTE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INCYTE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2022
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
291
+2.53%
|
$19,206
$66.64 P/Share
|
|
Sep 30
2022
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
339
+2.97%
|
$22,374
$66.64 P/Share
|
|
Sep 30
2022
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
914
+0.01%
|
-
|
|
Jul 22
2022
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,564
-8.12%
|
$129,812
$83.13 P/Share
|
|
Jul 07
2022
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
5,787
-12.55%
|
$457,173
$79.38 P/Share
|
|
Jul 07
2022
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
2,873
-3.8%
|
$226,967
$79.38 P/Share
|
|
Jul 05
2022
|
Thomas Tray Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
987
-4.87%
|
$77,973
$79.25 P/Share
|
|
Jul 05
2022
|
Paula J Swain EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,599
-3.16%
|
$205,321
$79.25 P/Share
|
|
Jul 05
2022
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,856
-2.73%
|
$304,624
$79.25 P/Share
|
|
Jul 05
2022
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,124
-1.52%
|
$88,796
$79.25 P/Share
|
|
Jul 05
2022
|
Maria E Pasquale EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,043
-4.57%
|
$240,397
$79.25 P/Share
|
|
Jul 05
2022
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,599
-5.34%
|
$205,321
$79.25 P/Share
|
|
Jul 05
2022
|
Herve Hoppenot Chairman / CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,174
-4.96%
|
$1,672,746
$79.25 P/Share
|
|
Jul 05
2022
|
Barry P Flannelly EVP & General Manager US |
SELL
Payment of exercise price or tax liability
|
Direct |
3,506
-4.44%
|
$276,974
$79.25 P/Share
|
|
Jul 05
2022
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-4.08%
|
$172,299
$79.25 P/Share
|
|
Jul 02
2022
|
Thomas Tray Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+17.0%
|
-
|
|
Jul 02
2022
|
Paula J Swain EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
9,921
+10.76%
|
-
|
|
Jul 02
2022
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,941
+11.82%
|
-
|
|
Jul 02
2022
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,317
+19.01%
|
-
|
|
Jul 02
2022
|
Maria E Pasquale EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,529
+16.89%
|
-
|
|
Jul 02
2022
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Grant, award, or other acquisition
|
Direct |
9,921
+16.92%
|
-
|
|
Jul 02
2022
|
Herve Hoppenot Chairman / CEO |
BUY
Grant, award, or other acquisition
|
Direct |
60,433
+12.4%
|
-
|
|
Jul 02
2022
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
13,529
+14.61%
|
-
|
|
Jul 02
2022
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,274
+17.43%
|
-
|
|
Jun 30
2022
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
236
+2.88%
|
$17,700
$75.97 P/Share
|
|
Jun 30
2022
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
275
+2.45%
|
$20,625
$75.97 P/Share
|
|
Jun 30
2022
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
321
+2.9%
|
$24,075
$75.97 P/Share
|
|
Jun 30
2022
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
866
+0.01%
|
-
|
|
Jun 28
2022
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,488
-8.58%
|
$861,600
$75.63 P/Share
|
|
Jun 15
2022
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,144
+38.68%
|
-
|
|
Jun 15
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,144
+14.17%
|
-
|
|
Jun 15
2022
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,144
+21.74%
|
-
|
|
Jun 15
2022
|
Katherine A High Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,144
+28.09%
|
-
|
|
Jun 15
2022
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,144
+17.05%
|
-
|
|
Jun 15
2022
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,144
+16.75%
|
-
|
|
Jun 15
2022
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
4,288
+0.04%
|
-
|
|
Apr 09
2022
|
Maria E Pasquale EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
517
-0.97%
|
$41,360
$80.95 P/Share
|
|
Apr 08
2022
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
43,993
-12.66%
|
$3,651,419
$83.23 P/Share
|
|
Apr 08
2022
|
Barry P Flannelly EVP & General Manager US |
BUY
Exercise of conversion of derivative security
|
Direct |
41,864
+19.17%
|
$2,930,480
$70.45 P/Share
|
|
Mar 31
2022
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
326
+3.78%
|
$25,754
$79.42 P/Share
|
|
Mar 31
2022
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
249
+1.38%
|
$19,671
$79.42 P/Share
|
|
Mar 31
2022
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
240
+4.13%
|
$18,960
$79.42 P/Share
|
|
Mar 31
2022
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
280
+3.19%
|
$22,120
$79.42 P/Share
|
|
Mar 31
2022
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
880
+0.01%
|
-
|
|
Mar 10
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
218,563
+0.19%
|
$15,736,536
$72.39 P/Share
|
|
Mar 09
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
70,517
+0.19%
|
$5,006,707
$71.72 P/Share
|
|
Mar 08
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.27%
|
$7,000,000
$70.67 P/Share
|
|
Mar 08
2022
|
Baker Bros. Advisors LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
40,000
+0.37%
|
$880,000
$22.05 P/Share
|
|
Feb 22
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
99,800
+0.27%
|
$6,786,400
$68.07 P/Share
|
|
Feb 18
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
133,032
+0.18%
|
$9,046,176
$68.4 P/Share
|